Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHESYS study.

Author information

Affiliations

  • 1. Department of Gastroenterology and Hepatology, AZ Groeninge Hospital, Kortrijk, Belgium.
      Authors
    • D'heygere F 1
    • George C 1
    (2 authors)
  • 2. Pôle Hépato-digestif, Unité Inserm U.1110, Université de Strasbourg, Laboratoire d'Excellence HepSys, Strasbourg, France.
      Authors
    • Habersetzer F 2
    (1 author)
  • 3. Southlake Regional Health Centre, Newmarket, ON, Canada.
      Authors
    • Tripathi D 3
    (1 author)
  • 4. Division of Gastroenterology, .Department of Medicine, NYU Langone Medical Center, New York University School of Medicine, New York, NY, USA.
      Authors
    • Q Pan C 4
    (1 author)
  • 5. Orlando Infectious Disease Center, Orlando, FL, USA.
      Authors
    • Giron JA 5
    (1 author)
    • Show all (7)

Annals of Hepatology, 01 Mar 2014, 13(2):303-304
https://doi.org/10.1016/s1665-2681(19)30896-8 PMID: 24558225 

Abstract 

No abstract provided.

Full text links 

Read article at publisher's site: https://doi.org/10.1016/s1665-2681(19)30896-8

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.